If you are wondering whether prescription GLP-1 treatment is a fit for you, you can complete a free eligibility assessment to see what next step makes sense
The TGA described the eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), as a rare but serious condition that may result in permanent visual impairment, including blindness and no treatment has been shown to improve visual acuity outcomes
In some embodiments, administration of a formulation or composition or device described herein in combination with an otic intervention (e.g., an intratympanic injection, a stapedectomy, a medical device implant, or a cell-based transplant) delays or prevents collateral damage to auris structures, e.g., irritation, cell damage, cell death, osteoneogenesis, and/or further neuronal degeneration, caused by the external otic intervention (e.g., installation of an external device and/or cells in the ear)
The Rise of GLP-1 Compounding During drug shortages, the FDA allows an alternative supply pathway known as compounding to fill demand
NAD(+)-dependent repair of damaged DNA by human cell extracts
A large study suggests GLP-1 drugs used for diabetes and obesity may be linked to reduced addiction risk and fewer overdoses, though more research is needed
